Australia's most trusted
source of pharma news
Posted 29 October 2024 AM
Telix has had a big month, and the last couple of weeks has added to it. It has formed a new company, had a co-founder step down, and the FDA has accepted its New Drug Application in an area of unmet medical need.
The radiopharmaceutical company announced a new spin-off subsidiary, Rhine Pharma, following its collaboration with Heidelberg University in Germany, which started in 2021. It will focus on prostate-specific membrane antigen targeting small molecules attached to either technetium-99m (99mTc) or rhenium-188 (188Re).
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.